Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

αDC1 Vaccine

Vaccine · Immune activation, directed at tumor neoantigens

Phase 2 Most advanced trial
1 Registered trials

What is αDC1 Vaccine?

αDC1 Vaccine is an autologous dendritic cell vaccine combining mature phenotype with high IL-12p70 production. It is loaded with tumor antigens and administered intradermally. The vaccine is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
tumor neoantigens (antigen)
Mechanism
Immune activation, directed at tumor neoantigens
Pathways
IL-12p70 production, T cell co-stimulation
Therapy area
Oncology
In trials of
AIM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07634094 Phase 2 Ovarian Cancer Not yet recruiting AIM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.